Compugen Ltd. (NASDAQ:CGEN) has received an average rating of “Buy” from the six brokerages that are currently covering the firm. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $10.33.
A number of research analysts have issued reports on the stock. FBR & Co restated a “buy” rating on shares of Compugen in a research report on Wednesday, June 22nd. Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th.
Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in shares of Compugen by 20.9% in the first quarter. Geode Capital Management LLC now owns 22,873 shares of the company’s stock worth $127,000 after buying an additional 3,959 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Compugen during the second quarter worth approximately $164,000. Menta Capital LLC boosted its position in shares of Compugen by 2.0% in the first quarter. Menta Capital LLC now owns 160,450 shares of the company’s stock worth $895,000 after buying an additional 3,100 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Compugen by 13.0% in the first quarter. BlackRock Fund Advisors now owns 653,230 shares of the company’s stock worth $3,645,000 after buying an additional 75,135 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of Compugen by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 45,787 shares of the company’s stock worth $293,000 after buying an additional 1,000 shares during the last quarter. 14.09% of the stock is owned by institutional investors.
Shares of Compugen (NASDAQ:CGEN) opened at 6.30 on Tuesday. The firm has a 50-day moving average of $6.86 and a 200-day moving average of $6.63. The firm’s market capitalization is $320.72 million. Compugen has a 1-year low of $4.32 and a 1-year high of $7.79.
Compugen (NASDAQ:CGEN) last released its earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. Compugen had a negative net margin of 245.83% and a negative return on equity of 26.46%. On average, equities research analysts anticipate that Compugen will post ($0.56) EPS for the current fiscal year.
Compugen Company Profile
Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.